• PacBio Sells Their Short-Read IP to Illumina

    Feb 03 | Bio-IT World | Yesterday, PacBio announced the completion of the sale of short-read DNA sequencing technology to Illumina. PacBio received $48.1 million in net cash proceeds from the transaction. The sale closed on January 30, 2026. More

  • Unlocking the Dangers of Disrupted Sleep

    Feb 03 | Bio-IT World | It has been known for some time now that for people with irregular sleep patterns, including shift workers and frequent travelers across time zones, disruptions to the body’s circadian rhythm can be deadly. The dangers have notably included heightened risk of aggressive breast cancer. More

  • Eli Lilly Gears Up for a Busy Year with a Diversified Pipeline

    Jan 29 | Bio-IT World | Earlier this month at the J.P. Morgan Healthcare Conference, Eli Lilly Chairman and CEO David Ricks spoke at a fireside chat and presented what the company has planned for 2026, which also marks its 150th anniversary. This year is expected to be a productive one in terms of clinical trial activity, wider availability of medicines, and expansion into new therapeutic areas. More

  • Follow the Money: Helicon Peptide Development, Next-Gen Obesity Metabolic Disease Therapies, Cell Stress Sensing Platform

    Jan 28 | Bio-IT World | Parabilis Medicines will continue the clinical development of FOG-001 (zolucatetide), the company’s lead investigational Helicon peptide; Alveus Therapeutics will advance into Phase 2 clinical development of ALV-100, the company’s lead program; Soley Therapeutics plans to advance its proprietary cell stress sensing platform; and more. More

  • BigHat, Revvity Collaborate with Eli Lilly, Immunai Signs Agreement with Bristol Myers Squibb, SandboxAQ Launches New AI Model

    Jan 27 | Bio-IT World | BigHat Biosciences and Revvity have entered collaborations with Eli Lilly and Company; Immunai has signed an agreement with Bristol Myers Squibb; SandboxAQ launches a new AI model; and more. More

  • Dealmakers Predict Banner Year as Biopharma M&A Momentum Builds

    Jan 23 | Bio-IT World | The mood at this year's J.P. Morgan Healthcare Conference signals a dramatic shift for biopharma dealmaking, with industry leaders projecting 2026 could eclipse last year's surging merger and acquisition activity. During an Endpoints News panel discussion, senior executives from AbbVie, Amgen, and Merck expressed confidence that favorable market conditions and breakthrough science are converging to create what one panelist called "a renaissance moment" for the sector. More

  • Improved Drug Safety Needs Better Data Before AI

    Jan 23 | Bio-IT World | Applying artificial intelligence (AI) to fragmented and incomplete safety data cannot fill the gap left when the right information has not been captured during initial patient adverse event reporting. And yet, software vendors position the technology as a quick fix to safety data complexity. Although AI definitely has a role to play, it would be far better to use it to refine the data capture process. More

  • AI in Pharma: Progress Made, But Data Challenges Persist

    Jan 20 | Bio-IT World | The pharmaceutical industry’s approach to artificial intelligence is maturing, with companies increasingly focused on innovation rather than mere efficiency gains. However, significant hurdles around data quality and workforce training continue to impede progress. More

  • 10x Genomics Positions Spatial Biology as Center Stage as AI Fuels New Wave of Customer Demand

    Jan 14 | Bio-IT World | At the 44th Annual J.P. Morgan Healthcare Conference, 10x Genomics announced a strong ending to 2025. With great anticipation for 2026, 10x Genomics remains centered on their mission on accelerating understanding of biology to advance human health, particularly in the single-cell and spatial biology areas. More

  • Illumina at JPM 2026: Strong Q4, Clinical Growth, and BioInsight Launch

    Jan 13 | Bio-IT World | Jacob Thaysen returned to the J.P. Morgan Healthcare Conference stage Tuesday with a message of momentum: Illumina is back to growth, and clinical sequencing is driving the train. In his third annual presentation as CEO, Thaysen unveiled preliminary fourth quarter results that exceeded expectations and introduced BioInsight, a new business unit aimed at accelerating drug discovery through AI-powered biological insights. More
View more articles
Bio IT World Lead Gen

 
Industry-spotlight

Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!

Industry-spotlight
Trends from the Trenches

Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what’s coming next.
Listen today!